Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor Analyst Event
| QSI Stock | USD 1.14 0.09 7.32% |
Under 57% of QuantumSi's investor base is looking to short. The analysis of the overall investor sentiment regarding QuantumSi suggests that many traders are alarmed. QuantumSi's investing sentiment shows overall attitude of investors towards QuantumSi.
QuantumSi |
Quantum-Si Incorporated , The Protein Sequencing Company, today announced the highlights of an In
Read at businesswire.com
 |
QuantumSi Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards QuantumSi can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
QuantumSi Fundamental Analysis
We analyze QuantumSi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of QuantumSi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of QuantumSi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
QuantumSi is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
QuantumSi Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with QuantumSi stock to make a market-neutral strategy. Peer analysis of QuantumSi could also be used in its relative valuation, which is a method of valuing QuantumSi by comparing valuation metrics with similar companies.
Peers
QuantumSi Related Equities
| CRBU | Caribou Biosciences | 8.91 | ||||
| VERV | Verve Therapeutics | 8.85 | ||||
| HOOK | Hookipa Pharma | 6.90 | ||||
| HRTX | Heron Therapeuti | 5.45 | ||||
| BEAM | Beam Therapeutics | 5.26 | ||||
| BDTX | Black Diamond | 4.05 | ||||
| NTLA | Intellia Therapeutics | 3.26 | ||||
| CRSP | Crispr Therapeutics | 3.10 | ||||
| ABOS | Acumen Pharmaceuticals | 2.73 | ||||
| SEER | Seer | 0.81 | ||||
| EDIT | Editas Medicine | 0.45 | ||||
| ALEC | Alector | 0.78 | ||||
| RNA | Avidity Biosciences | 1.07 | ||||
| PRME | Prime Medicine, | 1.20 | ||||
| NRIX | Nurix Therapeutics | 2.57 | ||||
| MNOV | MediciNova | 3.37 | ||||
| HCWB | HCW Biologics | 10.34 | ||||
| PASG | Passage Bio | 11.12 |
Complementary Tools for QuantumSi Stock analysis
When running QuantumSi's price analysis, check to measure QuantumSi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy QuantumSi is operating at the current time. Most of QuantumSi's value examination focuses on studying past and present price action to predict the probability of QuantumSi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move QuantumSi's price. Additionally, you may evaluate how the addition of QuantumSi to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |